Ethics in adherence promotion and monitoring

Cynthia S. Rand; Mary Ann Sevick

doi:10.1016/S0197-2456(00)00085-4

Ethics in adherence promotion and monitoring

Cynthia S. Rand, Mary Ann Sevick

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

In evaluating and intervening to increase adherence to medical treatments, clinicians and researchers must address ethical issues pertaining to best interest, autonomy, and privacy. 'Best interest' refers to the notion that health-care practitioners act in a manner that produces benefits or good outcomes for the patients in their care. 'Autonomy' refers to the patient's right to determine whether or not they will accept medical treatment or participate in a clinical study. 'Nonmaleficence' refers to the clinician's or researcher's responsibility to 'do no harm.' 'Privacy' refers to the notion that researchers and clinicians promise not to divulge personal information about the patients in their care. Adherence monitoring and promotion pose ethical challenges to researchers and clinicians, which are the topic of this paper. Control Clin Trials 2000;21:241S-247S Copyright (C) 2000 Elsevier Science Inc.

Original language	English (US)
Pages (from-to)	S241-S247
Journal	Controlled clinical trials
Volume	21
Issue number	5 SUPPL. 1
DOIs	https://doi.org/10.1016/S0197-2456(00)00085-4
State	Published - Dec 2000
Externally published	Yes

Keywords

Adherence
Ethics

ASJC Scopus subject areas

Pharmacology

Access to Document

10.1016/S0197-2456(00)00085-4

Cite this

@article{b642acf684dd49bb87d69a06556524e9,

title = "Ethics in adherence promotion and monitoring",

abstract = "In evaluating and intervening to increase adherence to medical treatments, clinicians and researchers must address ethical issues pertaining to best interest, autonomy, and privacy. 'Best interest' refers to the notion that health-care practitioners act in a manner that produces benefits or good outcomes for the patients in their care. 'Autonomy' refers to the patient's right to determine whether or not they will accept medical treatment or participate in a clinical study. 'Nonmaleficence' refers to the clinician's or researcher's responsibility to 'do no harm.' 'Privacy' refers to the notion that researchers and clinicians promise not to divulge personal information about the patients in their care. Adherence monitoring and promotion pose ethical challenges to researchers and clinicians, which are the topic of this paper. Control Clin Trials 2000;21:241S-247S Copyright (C) 2000 Elsevier Science Inc.",

keywords = "Adherence, Ethics",

author = "Rand, {Cynthia S.} and Sevick, {Mary Ann}",

note = "Funding Information: Support for this report was provided by the Claude D. Pepper Older Americans Independence Center of Wake Forest University through grant P60 AG10484 from the National Institutes of Health. Funding for the conference from which this paper evolved and the postconference publication was provided by Merck & Co., Inc., National Institute on Aging (1R13AG16229-01), NIH Office of Behavioral and Social Science Research, and Wyeth-Ayerst Laboratories. Additional support was provided by the Women's Health Center of Excellence (DHHS 282-97-0025).",

year = "2000",

month = dec,

doi = "10.1016/S0197-2456(00)00085-4",

language = "English (US)",

volume = "21",

pages = "S241--S247",

journal = "Controlled clinical trials",

issn = "0197-2456",

publisher = "Elsevier BV",

number = "5 SUPPL. 1",

}

TY - JOUR

T1 - Ethics in adherence promotion and monitoring

AU - Rand, Cynthia S.

AU - Sevick, Mary Ann

N1 - Funding Information: Support for this report was provided by the Claude D. Pepper Older Americans Independence Center of Wake Forest University through grant P60 AG10484 from the National Institutes of Health. Funding for the conference from which this paper evolved and the postconference publication was provided by Merck & Co., Inc., National Institute on Aging (1R13AG16229-01), NIH Office of Behavioral and Social Science Research, and Wyeth-Ayerst Laboratories. Additional support was provided by the Women's Health Center of Excellence (DHHS 282-97-0025).

PY - 2000/12

Y1 - 2000/12

N2 - In evaluating and intervening to increase adherence to medical treatments, clinicians and researchers must address ethical issues pertaining to best interest, autonomy, and privacy. 'Best interest' refers to the notion that health-care practitioners act in a manner that produces benefits or good outcomes for the patients in their care. 'Autonomy' refers to the patient's right to determine whether or not they will accept medical treatment or participate in a clinical study. 'Nonmaleficence' refers to the clinician's or researcher's responsibility to 'do no harm.' 'Privacy' refers to the notion that researchers and clinicians promise not to divulge personal information about the patients in their care. Adherence monitoring and promotion pose ethical challenges to researchers and clinicians, which are the topic of this paper. Control Clin Trials 2000;21:241S-247S Copyright (C) 2000 Elsevier Science Inc.

AB - In evaluating and intervening to increase adherence to medical treatments, clinicians and researchers must address ethical issues pertaining to best interest, autonomy, and privacy. 'Best interest' refers to the notion that health-care practitioners act in a manner that produces benefits or good outcomes for the patients in their care. 'Autonomy' refers to the patient's right to determine whether or not they will accept medical treatment or participate in a clinical study. 'Nonmaleficence' refers to the clinician's or researcher's responsibility to 'do no harm.' 'Privacy' refers to the notion that researchers and clinicians promise not to divulge personal information about the patients in their care. Adherence monitoring and promotion pose ethical challenges to researchers and clinicians, which are the topic of this paper. Control Clin Trials 2000;21:241S-247S Copyright (C) 2000 Elsevier Science Inc.

KW - Adherence

KW - Ethics

UR - http://www.scopus.com/inward/record.url?scp=0033833410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033833410&partnerID=8YFLogxK

U2 - 10.1016/S0197-2456(00)00085-4

DO - 10.1016/S0197-2456(00)00085-4

M3 - Article

C2 - 11018582

AN - SCOPUS:0033833410

SN - 0197-2456

VL - 21

SP - S241-S247

JO - Controlled clinical trials

JF - Controlled clinical trials

IS - 5 SUPPL. 1

ER -

Ethics in adherence promotion and monitoring

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this